Amphastar Pharmaceuticals, which manufactures generic and proprietary injectable drugs, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. The company's primary source of revenue is from a generic version of Sanofi's Lovenox. The Rancho Cucamonga, CA-based company, which was founded in 1996 and booked $223 million in sales for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol AMPH. Amphastar Pharmaceuticals filed confidentially on December 26, 2013. Jefferies, BMO Capital Markets and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
